| Ulcerative Colitis
Cyltezo vs Avsola
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Cyltezo vs Avsola with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAvsola has a higher rate of injection site reactions vs Cyltezo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Avsola but not Cyltezo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cyltezo
Avsola
At A Glance
SC injection
Every other week
TNF-alpha inhibitor
IV infusion
Every 6-8 weeks
TNF-alpha inhibitor
Indications
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Panuveitis
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Psoriasis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg every other week SC; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Crohn Disease, Ulcerative Colitis 160 mg on Day 1, 80 mg on Day 15, then 40 mg every other week SC starting Day 29.
Psoriasis vulgaris, Panuveitis 80 mg initial dose, then 40 mg every other week SC starting 1 week after initial dose.
Crohn Disease, Ulcerative Colitis, Arthritis, Psoriatic, Psoriasis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 8 weeks maintenance.
Rheumatoid Arthritis 3 mg/kg IV induction at weeks 0, 2, and 6, followed by 3 mg/kg every 8 weeks maintenance, in combination with methotrexate.
Ankylosing Spondylitis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 6 weeks maintenance.
Contraindications
—
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab products, any inactive ingredient of AVSOLA, or murine proteins
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, accidental injury, nausea, urinary tract infection, flu syndrome, abdominal pain, hyperlipidemia, back pain, hypertension, hematuria
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), malignancies, acute liver failure, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis
Most common (>10%) Infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Pneumonia, cellulitis, abscess, skin ulceration, sepsis, bacterial infection, lymphoma, hepatotoxicity
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute liver failure, anaphylactic shock, cerebrovascular accidents, myocardial ischemia
Pharmacology
Adalimumab-adbm is a TNF-alpha antagonist that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, modulating inflammatory responses and reducing concentrations of acute phase reactants such as CRP and ESR.
TNF-alpha inhibitor; chimeric IgG1kappa monoclonal antibody that neutralizes TNFalpha by binding with high affinity to the soluble and transmembrane forms of TNFalpha, inhibiting binding of TNFalpha with its receptors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cyltezo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Avsola
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Cyltezo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Avsola
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cyltezo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Avsola
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cyltezo.
No savings programs available for Avsola.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CyltezoView full Cyltezo profile
AvsolaView full Avsola profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.